In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...

The CoTikiS trial’s ten-week results from the 50-week trial saw as an endoscopic improvement rate of 32% in patients.

Using Cellectis' TALEN ® gene editing technology, we developed 'Smart CAR T cells' with the ability to express a ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...

"The companies selected for our Sales Training and Enablement Watchlist are making a significant impact with innovative ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R ...

Nantes and Paris - France, January 29, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Scienta Lab, a leader in Artificial Intelligence (AI)-driven precision ...

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO 13.01. OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as ...

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy Nantes and Paris - France, January 29, 2025 – 6:00pm CET ...